Effect of cilostazol on liver GSH (A) and MDA (B) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Time dependent activation of the pulmonary inflammatory response. by Marc-Alexander Oestreich (13961375)

Primers used in this study. by Hadi Alizadeh (20854757)

Subjects:

Effect of cilostazol on the serum ALT (A), AST (B) levels in rats with TAA-induced liver fibrosis. by Sally A. El Awdan (710176)

Effect of cilostazol on liver α-SMA (A) and COL-1 (B) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Apoptosis in thymus from cocaine-administered rats. by Kana Unuma (283272)

Subjects:

Aggrecan knockdown ATDC5 chondroprogenitor cells have decreased Alcian blue staining and absorbance levels compared to control cells after ITS stimulation. by Juanita K. Hodax (6848540)

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

The basic characteristics of the included studies. by Junyin Pan (20700411)

Subjects:

Common definitions and criteria for metabolic syndrome. by Junyin Pan (20700411)

Subjects:

Assessment of study bias in the included research. by Junyin Pan (20700411)

Subjects:

Results of the effect of dietary anthocyanins on health outcomes, including effect size and heterogeneity analysis. by Junyin Pan (20700411)

Subjects:

Risk of bias assessment for eligible randomized controlled trials. by Junyin Pan (20700411)

Subjects:

Summary of studies identified in the literature search, including studies excluded from the analysis and reasons for exclusion. by Junyin Pan (20700411)

Subjects:

The flow chart of study selection process. by Junyin Pan (20700411)

Subjects:

Data extracted from included studies for the systematic review and meta-analysis. by Junyin Pan (20700411)

Subjects:

Specifications and outcomes of clinical trial studies included in the meta-analysis. by Junyin Pan (20700411)

Subjects:

Glutathione metabolism decreases during infection with <i>P</i>. <i>aeruginosa</i> in a FadE2-dependent manner. by Siraje Arif Mahmud (3188391)

Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”